KOE:183490

Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, KOSDAQ, CEO, Annual general meeting, Polish Radiation Research Society, Homeostasis, RRS, Inflammation, Edwards Lifesciences, Patient, Pharmaceutical industry

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.
  • The abstract highlights the radio-mitigative potential of its lead investigational compound, EC-18 in gastrointestinal acute radiation syndrome.
  • The details of the presentation are as follows:
    We are excited to present our results at the 2022 RRS conference, that support EC-18s unique mechanism of action to potentially treat gastrointestinal acute radiation syndrome, said Ki Young Sohn, CEO & Chairman of Enzychem Lifesciences.
  • Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases.

Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Head, KOSDAQ, University, Clinical trial, Wastewater treatment, Patient, Radiation therapy, Inflammation, Edwards Lifesciences, M.D, International Society, HNC, Oral Oncology, Homeostasis, Pharmaceutical industry, Medical imaging, Cancer

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accepted for an Oral Proffered Paper at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) 2022 annual meeting, which will be held in hybrid on June 23-25, 2022 in Toronto, Canada.
  • The abstract highlights the new clinical data from Enzychems Phase 2 US clinical trial evaluating EC-18 in head and neck cancer (HNC) patients with chemoradiation-induced oral mucositis (CRIOM).
  • I am honored to present Enzychems clinical data at the MASCC/ISOO 2022 annual meeting, said Dr. Christina Henson.
  • Enzychem is headquartered in South Korea, with an office in the United States.

Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting

Retrieved on: 
Wednesday, April 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, University, Trial of the century, Clinical trial, Mucositis, Homeostasis, KOSDAQ, Inflammation, ASCO, Society, Radiation therapy, SOM, Edwards Lifesciences, American Society of Clinical Oncology, Patient, Pharmaceutical industry

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US clinical study data regarding its lead drug candidate, EC-18 for chemoradiation-induced oral mucositis (CRIOM) at the American Society of Clinical Oncology (ASCO) 2022 annual meeting, which will be held in-person on June 3-7th, 2022 in Chicago.
  • The abstract highlights the new clinical data from Enzychems Phase 2 US clinical trial evaluating the effect of EC-18 on severe oral mucositis (SOM) development in chemoradiation-treated head and neck cancer patients.
  • Dr. Christina Henson, a board-certified Radiation Oncologist and Residency Program Director for Radiation Oncology at the University of Oklahoma will present the following abstract.
  • Enzychem is headquartered in South Korea, with an office in the United States.

Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Retrieved on: 
Wednesday, March 9, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Safety, Head, Mucositis, OM, CSR, Incidence, STFU, Clinical study report, Inflammation, Analgesic, Edwards Lifesciences, Kaplan–Meier estimator, Mouth, Homeostasis, Pharynx, 2009 Tour de France, Stage 1 to Stage 11, Patient, KOSDAQ, SOM, AE, Pharmaceutical industry

An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.

Key Points: 
  • An iDSMB evaluated the safety endpoint every two weeks in a blinded fashion, until 30 days after the last dosing of Stage 1.
  • If a safety issue was noted, the iDSMB was instructed to unblind the treatment assignments to ascertain if the adverse event (AE) was associated with the study drug.
  • Since no safety issues were identified at the end of Stage 1, Stage 2 commenced using 2000 mg of the study drug, consistent with a positive safety outcome.
  • Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases.

Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Harvard School of Dental Medicine, KOSDAQ, Patient, Chemoradiotherapy, Population, Negotiation, CTO, Inflammation, FDA, Columbia University, Drug development, US, Edwards Lifesciences, CEO, Dentistry, Vanderbilt University, Emory University School of Medicine, Clinical trial, Technology transfer, Albert Einstein College of Medicine, Physician, Therapy, Pharmaceutical industry, Medical device

Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee.
  • To reinforce such corporate initiatives, and to start supporting the companys next stage activities, Enzychem has formed the Corporate Advisory Committee.
  • The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives.
  • Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones.